Theratechnologies (NASDAQ:THTX) Announces Quarterly Earnings Results, Misses Expectations By $0.14 EPS

Theratechnologies (NASDAQ:THTX) announced its quarterly earnings data on Wednesday. The company reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.14), Zacks reports.

Theratechnologies Stock Down 9.9 %

Shares of NASDAQ:THTX traded down $0.18 on Wednesday, hitting $1.64. 102,246 shares of the company traded hands, compared to its average volume of 106,274. The stock has a 50 day simple moving average of $1.75 and a 200-day simple moving average of $1.45. The company has a market cap of $75.18 million, a PE ratio of -16.35 and a beta of 1.26. Theratechnologies has a 52 week low of $1.08 and a 52 week high of $2.18.

Analyst Ratings Changes

Separately, Research Capitl raised Theratechnologies to a “strong-buy” rating in a research report on Friday, February 14th.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Theratechnologies stock. Bank of America Corp DE grew its holdings in Theratechnologies Inc. (NASDAQ:THTX) by 1,416.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 16,487 shares of the company’s stock after purchasing an additional 15,400 shares during the period. Bank of America Corp DE’s holdings in Theratechnologies were worth $30,000 as of its most recent SEC filing.

Theratechnologies Company Profile

Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.